Literature DB >> 2124743

In vivo use of OKT3: main issues for the monitoring of treated patients.

L Chatenoud1, C Ferran, J F Bach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2124743

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  3 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation.

Authors:  Mariela Glandt; Kevan C Herold
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

Review 3.  Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?

Authors:  Kevan C Herold; Lesley Taylor
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.